Source: International Congress 2017 – Management of COPD
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
V. Kostadinova (Varna, Bulgaria). Six months azithromycin treatment in COPD patients with high risk of further exacerbations. 3244

Member's Comments

No comment yet.

Related content which might interest you: Triple therapy for all patients with severe symptomatic COPD at risk of exacerbations Source: Eur Respir J, 53 (4) 1900147; 10.1183/13993003.00147-2019 Year: 2019 Long-term treatment with clarithromycin of stage II COPD patients with frequent exacerbations Source: Annual Congress 2008 - Management of COPD Year: 2008 β-blockers and risk of COPD exacerbation requiring hospitalisation in patients with COPD Source: Annual Congress 2011 - Biomarkers and exacerbations of asthma and COPD Year: 2011 Long-term azithromycin therapy in severe COPD with repeated exacerbations Source: Annual Congress 2010 - COPD exacerbation Year: 2010 COPD patients with asthma, characteristics and risk of exacerbations Source: International Congress 2019 – Multimorbidity in airway diseases and appropriate inhaled corticosteroid use in COPD Year: 2019 Budesonide is not associated with increased risk of pneumonia in COPD patients Source: Annual Congress 2009 - Exacerbations of COPD and bronchiectasis: aetiology and treatment Year: 2009 Effect of roflumilast on exacerbations in patients with severe COPD and a prior history of hospitalization taking combination therapy Source: International Congress 2015 – Advances in the future treatment of COPD Year: 2015 Ceruloplasmine efficacy in patients with asthma exacerbations Source: Annual Congress 2011 - Novel mechanisms in lung injury Year: 2011 Short-course pulmonary rehabilitation and exacerbations and activity of COPD patients over 1 year Source: International Congress 2018 – What’s new in lung function and exercise assessment in COPD? Year: 2018 Medication adherence in high exacerbation risk groups of COPD Source: International Congress 2016 – Novel avenues in the treatment of COPD II Year: 2016 The 1-year cost-effectiveness of roflumilast for the treatment of severe to very severe COPD patients Source: Eur Respir J 2007; 30: Suppl. 51, 194s Year: 2007 Statins and outcome of COPD patients after hospitalization for COPD exacerbations Source: Annual Congress 2010 - New treatments for asthma and COPD Year: 2010 Effect of azithromycin treatment on inflammation in COPD patients Source: International Congress 2019 – COPD clinical trials: inhaled and oral therapies Year: 2019 Telithromycin is effective in the treatment of patients with acute exacerbations of chronic bronchitis and risk factors for morbidity Source: Eur Respir J 2002; 20: Suppl. 38, 545s Year: 2002 Efficacy of azithromycin vs. ciprofloxacin in the treatment of patients with acute bacterial exacerbations of chronic obstructive pulmonary disease (COPD) Source: Eur Respir J 2002; 20: Suppl. 38, 544s Year: 2002 Decaf score for predicting treatment escalation in exacerbations of COPD Source: Virtual Congress 2020 – Clinical and functional evaluation of COPD Year: 2020 Risk factors for another hospitalization in COPD patients hospitalized for exacerbation Source: International Congress 2016 – Hospitalisation and comorbidities in chronic lung diseases Year: 2016 Are COPD patients with pneumonia who are taking inhaled corticosteroids at higher risk of dying? Source: Eur Respir J 2011; 37: 1-3 Year: 2011 Efficacy of levofloxacin (LVF) in the treatment of acute exacerbations of chronic bronchitis (AECB) in patients with risk factors Source: Annual Congress 2003 - Acute exacerbations of asthma and COPD Year: 2003 Reduced risk of next exacerbation and mortality associated with antibiotic use in COPD Source: Eur Respir J 2009; 33: 282-288 Year: 2009